Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Setmelanotide (Imcivree) is indicated for chronic weight management in adults and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome.
• The information was derived from a single study in the category of Systematic Reviews / Meta-Analyses.
• Imcivree has demonstrated significant efficacy in weight loss among patients with severe obesity associated with MC4R deficiency. The mean weight loss observed was substantial, averaging -6.91% during the treatment period.
• There is an age-related variability in response to therapy; adults experienced a greater impact than pediatric patients, evidenced by a mean difference in Body Mass Index scores of -10.55 kg/m^2 versus -0.61 kg/m^2, respectively.
• A potential side effect noted for Imcivree is skin hyperpigmentation, which may differ from other treatments' profiles, making it stand out as a specific safety consideration for this medication.
• Efficacy results underscore the importance of genetic testing and personalized medicine in obesity treatment. Populations suffering from POMC, PCSK1, LEPR deficiencies, or Bardet-Biedl syndrome have shown pronounced effectiveness when treated with Imcivree compared to traditional methods for genetically induced obese conditions.